alfuzosin has been researched along with Prostatitis in 11 studies
alfuzosin: structure given in first source
Prostatitis: Infiltration of inflammatory cells into the parenchyma of PROSTATE. The subtypes are classified by their varied laboratory analysis, clinical presentation and response to treatment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We conducted a multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy of alfuzosin, an alpha-adrenergic receptor blocker, in reducing symptoms in men with chronic prostatitis-chronic pelvic pain syndrome." | 9.13 | Alfuzosin and symptoms of chronic prostatitis-chronic pelvic pain syndrome. ( Alexander, RB; Anderson, RU; Berger, R; Chuai, S; Krieger, JN; Kusek, JW; Landis, JR; Liong, ML; Litwin, MS; McNaughton-Collins, M; Nadler, R; Nickel, JC; Nyberg, LM; O'Leary, M; Pontari, M; Schaeffer, AJ; Shoskes, DA; White, PC; Zeitlin, S, 2008) |
| "To perform a prospective, placebo-controlled study to examine the long-term efficacy of alfuzosin compared with placebo and standard therapy in patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), because alpha-blockers have been suggested for the treatment of CP/CPPS." | 9.10 | Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot study. ( Alas, P; Helström, PJ; Mehik, A; Nickel, JC; Sarpola, A, 2003) |
| "A double-blind, placebo-controlled study in 20 patients with 'prostatitis syndromes' and confirmed urodynamic abnormalities using the alpha 1-receptor-blocking compound alfuzosin is reported." | 9.07 | Research in 'prostatitis syndromes': the use of alfuzosin (a new alpha 1-receptor-blocking agent) in patients mainly presenting with micturition complaints of an irritative nature and confirmed urodynamic abnormalities. ( de Boo, T; de la Rosette, JJ; Debruyne, FM; Karthaus, HF; van Kerrebroeck, PE, 1992) |
| "We conducted a multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy of alfuzosin, an alpha-adrenergic receptor blocker, in reducing symptoms in men with chronic prostatitis-chronic pelvic pain syndrome." | 5.13 | Alfuzosin and symptoms of chronic prostatitis-chronic pelvic pain syndrome. ( Alexander, RB; Anderson, RU; Berger, R; Chuai, S; Krieger, JN; Kusek, JW; Landis, JR; Liong, ML; Litwin, MS; McNaughton-Collins, M; Nadler, R; Nickel, JC; Nyberg, LM; O'Leary, M; Pontari, M; Schaeffer, AJ; Shoskes, DA; White, PC; Zeitlin, S, 2008) |
| "This study shows that alfuzosin 10mg is well tolerated by young healthy subjects and may therefore be safely administered to young normotensive patients affected by distal ureteral stones and prostatitis." | 5.12 | Alfuzosin (10 mg) does not affect blood pressure in young healthy men. ( Bartoletti, R; Cai, T; Carini, M; Gavazzi, A; Geppetti, P; Giubilei, G; Gontero, P; Mondaini, N; Ungar, A, 2006) |
| "To perform a prospective, placebo-controlled study to examine the long-term efficacy of alfuzosin compared with placebo and standard therapy in patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), because alpha-blockers have been suggested for the treatment of CP/CPPS." | 5.10 | Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot study. ( Alas, P; Helström, PJ; Mehik, A; Nickel, JC; Sarpola, A, 2003) |
| "A double-blind, placebo-controlled study in 20 patients with 'prostatitis syndromes' and confirmed urodynamic abnormalities using the alpha 1-receptor-blocking compound alfuzosin is reported." | 5.07 | Research in 'prostatitis syndromes': the use of alfuzosin (a new alpha 1-receptor-blocking agent) in patients mainly presenting with micturition complaints of an irritative nature and confirmed urodynamic abnormalities. ( de Boo, T; de la Rosette, JJ; Debruyne, FM; Karthaus, HF; van Kerrebroeck, PE, 1992) |
| "Prostatitis is a common urologic diagnosis." | 2.43 | The management of chronic prostatitis in men with HIV. ( Lowe, FC; Santillo, VM, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 9 (81.82) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nickel, JC | 4 |
| Krieger, JN | 1 |
| McNaughton-Collins, M | 1 |
| Anderson, RU | 1 |
| Pontari, M | 1 |
| Shoskes, DA | 2 |
| Litwin, MS | 1 |
| Alexander, RB | 1 |
| White, PC | 1 |
| Berger, R | 1 |
| Nadler, R | 1 |
| O'Leary, M | 1 |
| Liong, ML | 1 |
| Zeitlin, S | 1 |
| Chuai, S | 1 |
| Landis, JR | 1 |
| Kusek, JW | 1 |
| Nyberg, LM | 1 |
| Schaeffer, AJ | 1 |
| Wagenlehner, FM | 1 |
| Weidner, W | 1 |
| Kattan, MW | 1 |
| Mehik, A | 1 |
| Alas, P | 1 |
| Sarpola, A | 1 |
| Helström, PJ | 1 |
| Mondaini, N | 1 |
| Giubilei, G | 1 |
| Ungar, A | 1 |
| Gontero, P | 1 |
| Cai, T | 1 |
| Gavazzi, A | 1 |
| Bartoletti, R | 1 |
| Geppetti, P | 2 |
| Carini, M | 1 |
| Santillo, VM | 1 |
| Lowe, FC | 1 |
| Magri, V | 2 |
| Trinchieri, A | 2 |
| Montanari, E | 1 |
| Del Nero, A | 1 |
| Mangiarotti, B | 1 |
| Zirpoli, P | 1 |
| de Eguileor, M | 1 |
| Marras, E | 2 |
| Ceriani, I | 2 |
| Vral, A | 1 |
| Perletti, G | 2 |
| Nassini, R | 1 |
| Materazzi, S | 1 |
| Benemei, S | 1 |
| de la Rosette, JJ | 1 |
| Karthaus, HF | 1 |
| van Kerrebroeck, PE | 1 |
| de Boo, T | 1 |
| Debruyne, FM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy Study of Tamsulosin and Tolterodine Treatment of Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome and Lower Urinary Tract Symptoms[NCT00913315] | 30 participants (Anticipated) | Interventional | 2009-08-31 | Not yet recruiting | |||
| A Randomized Clinical Trial to Evaluate the Efficacy and Safety of 10mg Alfuzosin in the Treatment of Chronic Prostatitis / Chronic Pelvic Pain Syndrome (CP/CPPS) in Recently-Diagnosed and/or Newly-Symptomatic Alpha-blocker Naïve Patients[NCT00103402] | Phase 3 | 272 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
For the Hospital Anxiety and Depression Scale, higher scores indicate greater anxiety and depression; range, 0 to 42. (NCT00103402)
Timeframe: Baseline and 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Alfuzosin | -2.6 |
| Placebo | -1.5 |
For the International Index of Erectile Function, higher scores indicate better sexual function; range, 0 to 75. (NCT00103402)
Timeframe: Baseline and 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Alfuzosin | 0.5 |
| Placebo | -0.2 |
For the Male Sexual Health Questionnaire, higher scores indicate better function with respect to erection and ejaculation and greater satisfaction with sexual life; range, 0 to 40. (NCT00103402)
Timeframe: Baseline and 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Alfuzosin | 1.7 |
| Placebo | 0.6 |
For the National Institutes of Health Chronic Prostatitis Symptom Index (NIHCPSI) total score, higher scores indicate more severe symptoms and scores range from 0 to 43. The primary outcome was a decline of at least 4 from baseline to 12 weeks (NCT00103402)
Timeframe: Baseline and 12 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Alfuzosin | 68 |
| Placebo | 66 |
For the Medical Outcomes Study Short Form Health Survey 12 (SF-12), higher scores indicate better quality of life. Score range for both the physical and mental component summaries is 0 to 100. (NCT00103402)
Timeframe: Baseline and 12 weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Physical component | Mental component | |
| Alfuzosin | 3.0 | 4.0 |
| Placebo | 3.5 | 1.9 |
For the McGill Pain Questionnaire, higher scores indicate greater pain. Score ranges are as follows: total score, 0 to 45; sensory score, 0 to 33; affective score, 0 to 12. (NCT00103402)
Timeframe: Baseline and 12 weeks
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Total score | Sensory score | Affective score | |
| Alfuzosin | -3.4 | -2.5 | -1.0 |
| Placebo | -3.1 | -2.3 | -0.9 |
For the National Institutes of Health Chronic Prostatitis Symptom Index (NIHCPSI), higher scores indicate more severe symptoms (for the quality-of-life score, higher scores indicate a more negative effect). Score ranges are as follows: total score, 0 to 43; pain score, 0 to 21; urinary score, 0 to 10, quality-of-life score, 0 to 12; and average pain and urgency scores, 0 to 10. (NCT00103402)
Timeframe: Baseline and12 weeks
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Total score | Pain score | Urinary score | Quality-of-life score | |
| Alfuzosin | -7.1 | -3.3 | -1.2 | -1.2 |
| Placebo | -6.5 | -3.0 | -1.0 | -1.2 |
3 reviews available for alfuzosin and Prostatitis
| Article | Year |
|---|---|
The management of chronic prostatitis in men with HIV.
Topics: Adrenergic alpha-Antagonists; Algorithms; Antiretroviral Therapy, Highly Active; Chronic Disease; Co | 2006 |
The concept of neurogenic inflammation.
Topics: Adrenergic alpha-Antagonists; Animals; Calcium Channels; Humans; Male; Nerve Tissue Proteins; Neurog | 2008 |
Role of alpha1-blockers in chronic prostatitis syndromes.
Topics: Adrenergic alpha-Antagonists; Anti-Infective Agents; Bacterial Infections; Chronic Disease; Clinical | 2008 |
4 trials available for alfuzosin and Prostatitis
| Article | Year |
|---|---|
Alfuzosin and symptoms of chronic prostatitis-chronic pelvic pain syndrome.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Chronic Disease; Humans; Male; Middle Aged; Pelvic Pain; | 2008 |
Alfuzosin and symptoms of chronic prostatitis-chronic pelvic pain syndrome.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Chronic Disease; Humans; Male; Middle Aged; Pelvic Pain; | 2008 |
Alfuzosin and symptoms of chronic prostatitis-chronic pelvic pain syndrome.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Chronic Disease; Humans; Male; Middle Aged; Pelvic Pain; | 2008 |
Alfuzosin and symptoms of chronic prostatitis-chronic pelvic pain syndrome.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Chronic Disease; Humans; Male; Middle Aged; Pelvic Pain; | 2008 |
Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot study.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Chronic Disease; Double-Blind Method; Humans; Male; Middl | 2003 |
Alfuzosin (10 mg) does not affect blood pressure in young healthy men.
Topics: Adrenergic alpha-Antagonists; Adult; Blood Pressure; Cross-Over Studies; Dose-Response Relationship, | 2006 |
Research in 'prostatitis syndromes': the use of alfuzosin (a new alpha 1-receptor-blocking agent) in patients mainly presenting with micturition complaints of an irritative nature and confirmed urodynamic abnormalities.
Topics: Adrenergic alpha-Antagonists; Adult; Double-Blind Method; Humans; Male; Middle Aged; Prostatitis; Qu | 1992 |
4 other studies available for alfuzosin and Prostatitis
| Article | Year |
|---|---|
Prostatitis: no benefit of alpha-blockers for chronic prostatitis.
Topics: Adrenergic alpha-Antagonists; Chronic Disease; Humans; Male; Prostatitis; Quinazolines; Randomized C | 2009 |
Phenotypically directed multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome: a prospective study using UPOINT.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Benzhydryl Compounds; Chronic Disease; Cohort | 2010 |
Reduction of PSA values by combination pharmacological therapy in patients with chronic prostatitis: implications for prostate cancer detection.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Algorithms; Androgen Antagonists; Anti-Bacterial Agents; | 2007 |
Eradication of unusual pathogens by combination pharmacological therapy is paralleled by improvement of signs and symptoms of chronic prostatitis syndrome.
Topics: Adrenergic alpha-Antagonists; Adult; Androgen Antagonists; Anti-Bacterial Agents; Anti-Infective Age | 2007 |